# To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin

> **NCT03247673** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 141 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CT-P16
- **DRUG:** EU-approved Avastin
- **DRUG:** US-licensed Avastin

## Key facts

- **NCT ID:** NCT03247673
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2017-12-22
- **Final completion:** 2018-01-17
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2020-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03247673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03247673, "To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03247673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*